Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD

The recruitment status of this study is unknown because the information has not been verified recently.

Verified November 2006 by Shaheed Beheshti Medical University. Recruitment status was Recruiting

First Received on August 30, 2006. Last Updated on November 13, 2006 History of Changes

Sponsor:	Shaheed Beheshti Medical University
Information provided by:	Shaheed Beheshti Medical University
ClinicalTrials.gov Identifier:	NCT00370539

Purpose

To compare the efficacy and safety of photodynamic therapy (PDT) combined with intravitreal bevacizumab versus combination of photodynamic therapy , intravitreal bevacizumab and intravitreal triamcinolone for neovascular AMD.

Condition	Intervention	Phase
Neovascular Age-Related Macular Degeneration	Drug: verteporfin, bevacizumab, triamcinolone acetonide	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind Primary Purpose: Treatment

Resource links provided by NLM:

Genetics Home Reference related topics: age-related macular degeneration X-linked juvenile retinoschisis

MedlinePlus related topics: Macular Degeneration

Drug Information available for: Triamcinolone diacetate Triamcinolone acetonide Verteporfin Bevacizumab Triamcinolone Triamcinolone hexacetonide

U.S. FDA Resources

Further study details as provided by Shaheed Beheshti Medical University:

Primary Outcome Measures:

Visual acuity

Secondary Outcome Measures:

Central macular thickness
Leakage in fluorescein angiography
Intraocular pressure
Anterior chamber reaction

Study Start Date:	September 2006
Estimated Study Completion Date:	November 2006

Eligibility

Ages Eligible for Study:	50 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Cases of active neovascular AMD with visual acuity of 20/400- 20/40

Exclusion Criteria:

History of glaucoma or ocular hypertension
Disciform scar

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00370539

Contacts

Contact: Hamid Ahmadieh, MD

+98 21 22585952

hahmadieh@hotmail.com

Locations

Iran, Islamic Republic of
Hamid Ahmadieh, MD	Recruiting
Tehran, Iran, Islamic Republic of, 16666
Contact: Hamid Ahmadieh, MD +98 21 22585952 hahmadieh@hotmail.com

Sponsors and Collaborators

Shaheed Beheshti Medical University

Investigators

Principal Investigator:

Hamid Ahmadieh, MD

Ophthalmic Research Center of Shaheed Beheshti Medical University

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00370539 History of Changes
Other Study ID Numbers:	8542
Study First Received:	August 30, 2006
Last Updated:	November 13, 2006
Health Authority:	Iran: Ethics Committee

Keywords provided by Shaheed Beheshti Medical University:

Photodynamic therapy,
Bevacizumab,
Triamcinolone,
Age-related macular degeneration,
Choroidal neovascular membrane

Additional relevant MeSH terms:

Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Triamcinolone hexacetonide
Triamcinolone Acetonide
Triamcinolone
Triamcinolone diacetate
Verteporfin
Bevacizumab
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Glucocorticoids

Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunosuppressive Agents
Immunologic Factors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Photosensitizing Agents
Radiation-Sensitizing Agents
Dermatologic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents

ClinicalTrials.gov processed this record on February 09, 2012